Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.75 |
| ▸ | POLB | P06746 | 4/20 | 0.75 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | GALK1 | P51570 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 2/20 | 0.57 |
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17779681 | 1.00 | MEN1 (0.75) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL6887329 | 0.92 | MEN1 (0.71) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL6887336 | 0.92 | MEN1 (0.71) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL25055325 | 0.89 | MEN1 (0.67) | MEN1KMT2APOLBAKR1B1BLM | |
| SCHEMBL20837899 | 0.89 | KMT2A (0.71) | MEN1KMT2APOLBAKR1B1PTPN1 | |
| SCHEMBL20837934 | 0.88 | AKR1B1 (0.63) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL17779690 | 0.88 | AKR1B1 (0.63) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL17769003 | 0.86 | KMT2A (0.64) | MEN1KMT2APOLBAKR1B1PTPN1 | |
| SCHEMBL18102843 | 0.84 | AKR1B1 (0.58) | MEN1KMT2APOLBPSMD14AKR1B1 | |
| SCHEMBL31284000 | 0.84 | PTPN1 (0.61) | MEN1KMT2APOLBPSMD14AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2023-02-21 | — | — | US | disclosed |
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2023-02-21 | — | — | US | disclosed |
| US-20220267286-A2 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-08-25 | — | — | US | disclosed |
| EP-4029859-A1 | 2-OXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-07-20 | — | — | EP | disclosed |
| US-20220041566-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-02-10 | — | — | US | disclosed |
| US-11117877-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2021-09-14 | — | — | US | disclosed |
| US-11117877-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2021-09-14 | — | — | US | disclosed |
| US-20190092737-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM2 - Biomolecular Simulations Lda. (PT) | 2019-03-28 | — | — | US | disclosed |
| US-20190092737-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM2 - Biomolecular Simulations Lda. (PT) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117877-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | TTR, TTPA, MTPN | MEN1 3201/4885KMT2A 3839/4885POLB 3855/4885 |
| US-20220267286-A2 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | MEN1 3061/4885KMT2A 3693/4885POLB 4384/4885 |
| US-20190092737-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | MEN1 3201/4885KMT2A 3839/4885POLB 3855/4885 |
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | TTR, TTPA, MTPN | MEN1 3061/4885KMT2A 3693/4885POLB 4384/4885 |
| US-20220041566-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | MEN1 3061/4885KMT2A 3693/4885POLB 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.